258 related articles for article (PubMed ID: 26203861)
1. Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
Hong J; Sha S; Zhou L; Wang C; Yin J; Chen L
Cell Death Dis; 2015 Jul; 6(7):e1832. PubMed ID: 26203861
[TBL] [Abstract][Full Text] [Related]
2. Sigma-1 (σ₁) receptor deficiency reduces β-amyloid(25-35)-induced hippocampal neuronal cell death and cognitive deficits through suppressing phosphorylation of the NMDA receptor NR2B.
Yin J; Sha S; Chen T; Wang C; Hong J; Jie P; Zhou R; Li L; Sokabe M; Chen L
Neuropharmacology; 2015 Feb; 89():215-24. PubMed ID: 25286118
[TBL] [Abstract][Full Text] [Related]
3. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease.
Shao QH; Chen Y; Li FF; Wang S; Zhang XL; Yuan YH; Chen NH
Acta Pharmacol Sin; 2019 Dec; 40(12):1503-1512. PubMed ID: 31388087
[TBL] [Abstract][Full Text] [Related]
4. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
5. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.
Kim HW; Choi WS; Sorscher N; Park HJ; Tronche F; Palmiter RD; Xia Z
Neurobiol Aging; 2015 Sep; 36(9):2617-27. PubMed ID: 26070241
[TBL] [Abstract][Full Text] [Related]
6. A role for glia maturation factor dependent activation of mast cells and microglia in MPTP induced dopamine loss and behavioural deficits in mice.
Selvakumar GP; Ahmed ME; Thangavel R; Kempuraj D; Dubova I; Raikwar SP; Zaheer S; Iyer SS; Zaheer A
Brain Behav Immun; 2020 Jul; 87():429-443. PubMed ID: 31982500
[TBL] [Abstract][Full Text] [Related]
7. Sigma-1 receptor knockout increases α-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra.
Hong J; Wang L; Zhang T; Zhang B; Chen L
Neurobiol Aging; 2017 Nov; 59():171-183. PubMed ID: 28870519
[TBL] [Abstract][Full Text] [Related]
8. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model.
Qi X; Davis B; Chiang YH; Filichia E; Barnett A; Greig NH; Hoffer B; Luo Y
J Neurochem; 2016 Sep; 138(5):746-57. PubMed ID: 27317935
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
11. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
12. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
[TBL] [Abstract][Full Text] [Related]
13. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T
J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
Pariyar R; Bastola T; Lee DH; Seo J
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216503
[TBL] [Abstract][Full Text] [Related]
15. Tonic Activation of NR2D-Containing NMDARs Exacerbates Dopaminergic Neuronal Loss in MPTP-Injected Parkinsonian Mice.
Sharma R; Neupane C; Pham TL; Lee M; Lee S; Lee SY; Nam MH; Kim CS; Park JB
J Neurosci; 2023 Nov; 43(46):7730-7744. PubMed ID: 37726169
[TBL] [Abstract][Full Text] [Related]
16. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
17. Sigma-1 receptor regulates mitophagy in dopaminergic neurons and contributes to dopaminergic protection.
Wang M; Wan C; He T; Han C; Zhu K; Waddington JL; Zhen X
Neuropharmacology; 2021 Sep; 196():108360. PubMed ID: 33122030
[TBL] [Abstract][Full Text] [Related]
18. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
Stayte S; Rentsch P; Li KM; Vissel B
PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.
Al-Sweidi S; Morissette M; Bourque M; Di Paolo T
Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296
[TBL] [Abstract][Full Text] [Related]
20. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]